Jarosław Dębniak

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen

Jolanta Kupryjańczyk, T Szymańska, Radosław Mądry et al. · British Journal of Cancer · 2003 · 81 citations · Full text

Prognostic impact of <i>BRCA1</i> pathogenic and <i>BRCA1/BRCA2</i> unclassified variant mutations in patients with ovarian carcinoma

E. Majdak, Jarosław Dębniak, Tomasz Milczek et al. · Cancer · 2005 · 65 citations

High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland

Izabela Brożek, Karolina Ochman, Jarosław Dębniak et al. · Gynecologic Oncology · 2007 · 56 citations

Somatic Variant, Tumor Heterogeneity, Medicine +8

P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens

Joanna Plisiecka-Hałasa, G Karpińska, T Szymańska et al. · Annals of Oncology · 2003 · 53 citations · Full text

Platinum-based Regimens, Ovarian Carcinomas, Medicine +9

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients

Magdalena Koczkowska, Natalia Krawczyńska, Maciej Stukan et al. · Cancers · 2018 · 40 citations · Full text